Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — PharmAust — Investor Presentation (July 2019)
17 slides from Neurizon Therapeutics's investor presentation, Jul 25, 2019
Slide 1: Presentation (25th July 2019)
ASX: PAA ACN 094 006 023 Presentation (25th July 2019) 1
Slide 2: Corporate Structure
Corporate Structure Epichem Pitney Pharmaceuticals Investor Presentation (25th July 2019) 2
Slide 3: Corporate Snapshot
Corporate Snapshot ASX Code: PAA Total Shares on Issue 280,221,192 Market Cap at $0.064 $17.65 Options (Unlisted) 56,895,412 Cash (approx.) $2M Debt (EFIC) $325K Top 20 Own 37% Epichem Revenue Forecast $4.2M Board/Exec Own 9.3% 2019-2020 Investor Presentation (25th July 2019) 3
Slide 4: Strategic Overview
Strategic Overview • PharmAust: Clinical-stage oncology company • Lead product is Monepantel (MPL) – a repurposed drug already approved for Veterinary use by Elanco US Inc • PharmAust patented MPL as an anti-cancer drug • Clinical strategy targeting MPL for vet and human applications • Option Agreem
Slide 5: Experienced Board & Management Team
Experienced Board & Management Team Dr. Roger Aston, Executive Chairman Sam Wright, Director & Company Secretary • > 30 years experience in the pharmaceutical and • > 20 years experience in biotech and healthcare. healthcare industries. • Extensive experience in relation to public company • Director
Slide 6: Monepantel Oncology Programme: Preparing for Pivotal Phase II Trial in Canine Cancer During 2019
Monepantel Oncology Programme: Preparing for Pivotal Phase II Trial in Canine Cancer During 2019 Investor Presentation (25th July 2019) 6
Slide 7: Clinical Outcomes To Commercial Opportunities
Clinical Outcomes To Commercial Opportunities Pilot phase II (2017) in lymphoma trial in dogs Shows MPL effective at Progression-Free Survival Using poor formulation Extensive Reformulation Program: 2018 - 2019 Extensive Phase I Program During 2019 Establishes Establishes New, High Dose, Palatable T
Slide 8: Why MPL for Cancer?
Why MPL for Cancer? ON MARKET OPTION DRUG AGREEMENT NOW OWNED RESEARCHED BY ELANCO BY VOC & OTHERS Investor Presentation (25th July 2019) 8
Slide 9: >$2 Billion market for approved mTOR Drugs
>$2 Billion market for approved mTOR Drugs Drug Approved Indications Company 2016 Sales (US$m)1 Sirolimus Transplantation Pfizer 170 Transplantation Renal Cell Carcinoma Rapalogues Breast Cancer Novartis/Pfizer >2,000 (Afinitor/Torisel) Pancreatic Neuroendocrine Tumours Mantle Cell Lymphoma 1. Globa
Slide 10: Trends in Companion Animal Health Market (US:2016)
Trends in Companion Animal Health Market (US:2016) US Dog/Cat $ Total Pet Expenditure: $70b1 Populations (2016)1 Vet Care Expenditure $17b1 Pet drug market $10.2b by 20182 (8% CAGR) 94m 90m Willingness to pay more for treatment3 ($2K-$5K/treatment) 1. http://www.americanpetproducts.org/press_industr
Slide 11: Pets and Cancer
Pets and Cancer ● 1 in 4 dogs die of cancer ● Pets are living longer (50% dogs > 10 yrs die of cancer) ● 6 million dogs diagnosed with cancer in US/yr ● Significant unmet need for new oncology drugs (US$500m - USD$1b market) ● Side effects associated with products and treatments are limiting market
Slide 12: Elanco strategically enters therapeutic oncology arena by the purchase of Aratana
Elanco strategically enters therapeutic oncology arena by the purchase of Aratana Elanco Global No. 3 Animal Health Company Investor Presentation (25th July 2019) 12
Slide 13: Product Areas of Focus
Product Areas of Focus Elanco is an established leader with flagship brands and a global presence. They’re focused on investing and innovating in the animal health priorities that mean the most to their customers and the animals in their care. COMPANION ANIMAL FOOD ANIMAL Investor Presentation (25th
Slide 14: Epichem
Our Australian chemistry team are expert service providers for: • Synthetic & Medicinal Chemistry • Pharmaceutical Reference Materials Epichem • Custom Synthesis • Analytical Chemistry • Technical Problem Solving • 15 Years success in helping clients worldwide Our mission is to deliver world-class i
Slide 15: Epichem has the best equipped private laboratories in the Southern Hemisphere
Epichem has the best equipped private laboratories in the Southern Hemisphere for small molecule synthesis Our Facility • State-of-the-Art laboratories purpose built in 2015 and expanded in 2018. • Nineteen fume hoods and room to grow. • Leading-edge technology for organic synthesis on a milligram t
Slide 16: PharmAust – current status and next steps
PharmAust – current status and next steps • Successful rights issue earlier in year (cash now $2m) • Successful micronisation and tablet manufacture • Phase II canine trial on dogs with lymphoma – imminent • Open label trial – interim dossier to be presented to Elanco Nov/Dec 2019 • Elanco Option Ag
Slide 17: Disclaimer
Disclaimer This presentation has been prepared by PharmAust Limited (ASX: PAA) (ACN: 094 006 023) (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents